Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea
Phase 2
Active, not recruiting
- Conditions
- Vaccine Adverse ReactionCOVID-19Sars-CoV-2 InfectionHealthy Volunteer
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 200
- Registration Number
- NCT05409300
- Locations
- 🇬🇳
Centre de recherche de Landreah, Conakry, Guinea
🇬🇳Palais du Peuple, Conakry, Guinea
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Phase 2
Active, not recruiting
- Conditions
- COVID-19SARS CoV 2 InfectionVaccine Adverse ReactionVaccine Reaction
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 200
- Registration Number
- NCT05409261
- Locations
- 🇲🇱
CVD-MALI, Bamako, Mali
Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women
Phase 4
Not yet recruiting
- Conditions
- Hepatitis B Virus - Chronic Active
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 150
- Registration Number
- NCT05403047
Aging With HIV and Neurocognitive Decline, a Follow-up Study
Not Applicable
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 282
- Registration Number
- NCT05385588
- Locations
- 🇫🇷
Hôpital Pellegrin, Bordeaux, France
🇫🇷Hôpital Saint André, Bordeaux, France
🇫🇷CH Cannes, Cannes, France
Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)
Not yet recruiting
- Conditions
- HIV Infections
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 603
- Registration Number
- NCT05312918
- Locations
- 🇨🇮
CIRBA, Abidjan, Côte D'Ivoire
🇲🇱SEREFO, Bamako, Mali
🇹🇬Biolim/Fss/Ul, Lomé, Togo
Variants of SARS-CoV-2 Causing COVID-19 in Africa
- Conditions
- COVID-19
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 12600
- Registration Number
- NCT05311891
- Locations
- 🇧🇫
Centre de Référence pour les pathogènes émergents et réémergent, Bobo-Dioulasso, Burkina Faso
🇹🇩Centre Hospitalier Universitaire la Référence Nationale (CHU-RN), N'Djamena, Chad
🇨🇬Laboratoire National de Santé Publique Brazzaville, Brazzaville, Congo
Transmission of Covid-19 During Clubbing Events in Closed Places
Not Applicable
Completed
- Conditions
- Healthy Participant
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 1216
- Registration Number
- NCT05311865
- Locations
- 🇫🇷
ANRS, Paris, France
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
Phase 2
Recruiting
- Conditions
- HIV/AIDS and Infections
- Interventions
- Drug: Recombinant human monoclonal antibody (bNAbs)Drug: Placebo
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 69
- Registration Number
- NCT05300035
- Locations
- 🇫🇷
Hôpial Avicenne - SMIT, Bobigny, France
🇫🇷Hôpital Antoine Béclère, Clamart, France
🇫🇷Hôpital Beaujon - Service de médecine interne, Clichy, France
Expectation, Motivation and Experience of HIV-patients Regarding Participation to an HIV Cure-related Clinical Trial
Terminated
- Conditions
- HIV Seropositivity
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 6
- Registration Number
- NCT05280392
- Locations
- 🇨🇭
CHUV, Lausanne, Switzerland
A pilot open label phase I trial to evaluate the safety and the tolerability of a combination of two HIV-1 inducers in HIV+ sub-type B patients under cART with undetectable viral load
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- ANRS Maladies Infectieuses Emergentes
- Target Recruit Count
- 15
- Registration Number
- 2024-518141-13-00
- Locations
- 🇧🇪
CHU Saint-Pierre, Bruxelles, Belgium